Oncomine, TIMER and GEPIA web-based tools were used to evaluate and validate the mRNA expression of CDK-1 and CDK-4 in different cancer types (solid tumor and hematological malignancies), different CRC sections as well as clinico-pathological parameters of CRC in relation to normal tissues. This evidence concerns the gene CDK1 and cancer.